Molecular Cancer

CORRECTION

Open Access

Correction: Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA

Min Kang[1,2,3*], Bo Tang[1,4*], Jixi Li[1], Ziyan Zhou[1], Kang Liu[1], Rensheng Wang[3], Ziyan Jiang[2,5], Fangfang Bi[2,6], David Patrick[2], Dongin Kim[7], Anirban K. Mitra[8,9] and Yang Yang-Hartwich[2,10*]

Correction: Mol Cancer 19, 143 (2020)
https://doi.org/10.1186/s12943-020-01248-9

Recently in a re-examination of our previously published paper [1], "Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA" [Molecular Cancer 19, article number 143 (2020)], we found two errors.

The first error is that we presented the wrong primer sequences for GAPDH in the Supplemental Methods (in the Additional file 2). We mistakenly listed the primer sequences for human β-actin (*ACTB*) as for GAPDH. The correct primer sequences for GAPDH are 5′-AATGAA GGGGTCATTGATGG −3′ and 5′-AAGGTGAAGGTC GGAGTCAA −3′. These were used in this study. Please find the resized Additional file 2 in the attachment.

The other error is a misplaced western blot image for the loading control β-actin in Fig. 4e. We have identified the correct image for β-actin bands. The following is the corrected figure.



They are minor errors, and their correction does not affect the conclusion of this article, however, we sincerely

The online version of the original article can be found at https://doi.org/10.1186/s12943-020-01248-9.

*Correspondence:
Min Kang
km1019@163.com
Bo Tang
dr_sntangbo@163.com
Yang Yang-Hartwich
yang.yang@yale.edu
[1]The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530022, China
[2]Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, CT 06510, USA
[3]Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China
[4]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China
[5]The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China
[6]Sheng Jing Hospital of China Medical University, Shenyang, Liaoning 110004, China
[7]Department of Pharmaceutical Sciences College of Pharmacy, University of Oklahoma, Oklahoma City, OK 73117, USA
[8]Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN 46202, USA
[9]Indiana University School of Medicine-Bloomington, Bloomington, IN 47405, USA
[10]Yale Cancer Center, New Haven, CT 06510, USA

apologize to the readers and editors for the inconvenience caused by our mistakes. We would like to ask for an opportunity to publish this correction.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12943-024-02111-x.

Additional file 2. This section describes the details of experimental procedures and materials that are not described in the Method Section, including Supplemental methods and lists of primers, antibodies, and plasmids.

Published online: 12 September 2024

References

1. Kang M, Tang B, Li J, et al. Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA. Mol Cancer. 2020;19:143. https://doi.org/10.1186/s12943-020-01248-9.

Publisher's note